(Q30671400)

26 June 2017

Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial (English)

1 reference

26 June 2017

J D Brandt

1

1 reference

26 June 2017

A M VanDenburgh

2

1 reference

26 June 2017

K Chen

3

1 reference

26 June 2017

S M Whitcup

4

1 reference

26 June 2017

Bimatoprost Study Group

5

1 reference

26 June 2017

1 June 2001

1 reference

26 June 2017

1 reference

26 June 2017

108

1 reference

26 June 2017

1023-31; discussion 1032

1 reference

26 June 2017

6

1 reference

Replacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compounds

26 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

Timolol hemihydrate vs timolol maleate to treat ocular hypertension and open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

Rank Transformations as a Bridge Between Parametric and Nonparametric Statistics

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

A useful testing strategy in phase III trials: combined test of superiority and test of equivalence

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

Why do some people go blind from glaucoma?

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

Ocular Beta-Blockers and Systemic Effects

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

Antiglaucoma medications: a review of safety and tolerability issues related to their use.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

Shortterm “escape” and longterm “drift.”. The dissipation effects of the beta adrenergic blocking agents

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

Systemic side effects of topical beta-adrenergic blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900584-X

7 January 2021

10.1016/S0161-6420(01)00584-X

Identifiers

DOI

1 reference

26 June 2017

1 reference